Established in 2019, Gujarat Kidney and Super Speciality Limited (GKASSL) is an emerging healthcare provider delivering secondary and tertiary care across Gujarat. The company currently operates a network of seven multispeciality hospitals and four pharmacies, strategically located in hubs such as Vadodara, Godhra, Bharuch, Borsad, and Anand.

GKASSL maintains a robust physical footprint with a total bed capacity of 490. Key facilities include the flagship Gujarat Kidney and Superspeciality Hospital and specialized centers like Raj Palmland and Surya Hospital. The company’s clinical spectrum ranges from general surgical treatments to high-complexity super-speciality procedures. Key therapeutic areas include: specialized care (internal medicine, orthopedics, and non-interventional cardiology), surgical excellence (minimally invasive procedures and general surgery) and ancillary services (integrated pharmacy operations via the Ashwini Medical Store network).

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

*Market cap @upper band

• Pre-eminence in renal sciences, with established sub-super specialties in urology
• Asset light business model with focus in central region of Gujarat
• Ability to attract, retain skilled and experienced quality medical professionals
• Track record of operating and financial performance and growth

The Company GUJARAT KIDNEY & SUPER SPECIALITY LIMITED IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

• Proposed acquisition of Parekhs Hospital at Ahmedabad (Rs. 77 Cr.)
• Part-payment of purchase consideration for the already acquired “Ashwini Medical Centre” (Rs. 12.40 Cr.)
• Funding of capital expenditure requirements of the Company towards setting up of a new hospital in Vadodara (Rs. 30.10 Cr.)
• Buying robotics equipment for our hospital Gujarat Kidney & Super Speciality hospital in Vadodara location (Rs. 6.83 Cr.)
• Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by the Company (Rs. 1.20 Cr.)
• Funding inorganic growth through unidentified acquisitions and General Corporate Purposes
• Acquisition of additional shareholding in the subsidiary namely “Harmony Medicare Private Limited” at Bharuch (Rs. 10.78 Cr.)

At the upper band of IPO Rs. 114, the stock is valued at 41.59 P/E multiple. Hence, well-informed investors subscribe for medium to long term perspective.